폴라리스AI파마
Financials
Valuation Metrics
폴라리스AI파마's Market Cap is ₩724B. At end of 2025 it was ₩828B. Ranked #1432 of 2,410 in KR market (top 59%), #813 of 1,631 on KOSDAQ (top 50%), #157 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 68%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 72.39B KRW | KR#1,432/2,410 Sec#157/231 |
| Revenue | 57.37B KRW | KR#1,718/2,410 Sec#116/231 |
| Net Income | 14.28B KRW | KR#833/2,410 Sec#56/231 |
| Total Assets | 196.69B KRW | KR#1,322/2,410 Sec#96/231 |
| Net Assets | 147.88B KRW | KR#1,145/2,410 Sec#81/231 |
| Employees | 164 | KR#1,243/2,410 Sec#102/231 |
| Value | ||
| P/E | 5.07x | KR#412/2,410 Sec#15/231 |
| P/B | 0.49x | KR#852/2,410 Sec#38/231 |
| PEG | 0.02x | KR#229/2,410 Sec#12/231 |
| P/S | 1.26x | KR#1,593/2,410 Sec#92/231 |
| EV/EBITDA | 29.00x | KR#1,202/2,410 Sec#73/231 |
| FCF Yield | 11.43% | KR#595/2,410 Sec#22/231 |
| Profitability | ||
| ROE | 9.66% | KR#645/2,410 Sec#44/231 |
| ROA | 7.26% | KR#492/2,410 Sec#38/231 |
| Op. Margin | 4.47% | KR#1,028/2,410 Sec#74/231 |
| Revenue Growth | 0.72% | KR#1,479/2,410 Sec#147/231 |
| Earnings Growth | 207.19% | KR#240/2,410 Sec#15/231 |
| Financial Health | ||
| Debt Ratio | 33.01% | KR#649/2,410 Sec#76/231 |
| Total Debt | 36.50B KRW | KR#1,135/2,410 Sec#81/231 |
| FCF | 8.28B KRW | KR#764/2,410 Sec#43/231 |
| Cash | 34.54B KRW | KR#922/2,410 Sec#61/231 |
| Current Ratio | 8.31x | KR#138/2,410 Sec#29/231 |
| Net Debt/EBITDA | 0.76x | KR#708/2,410 Sec#46/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,410 Sec—/231 |
| Performance | ||
| 1Y Return | -15.11% | KR#932/2,410 Sec#58/231 |
| 1M Return | -0.37% | KR#447/2,410 Sec#46/231 |
| From 52W High | -46.57% | KR#1,005/2,410 Sec#70/231 |
| 1Y MDD | -51.79% | KR#1,023/2,410 Sec#83/231 |
| Trading | ||
| Volume | 19,798 shares | KR#1,791/2,410 Sec#182/231 |
| Trading Value | 107.4M KRW | KR#1,665/2,410 Sec#178/231 |
| Foreign Own. | 1.68% | KR#1,758/2,410 Sec#170/231 |
| Per Share | ||
| EPS | 1,075 KRW | KR#697/2,410 Sec#47/231 |
| BPS | 11,132 KRW | KR#923/2,410 Sec#63/231 |
Company Info
Established in 1999 and listed on KOSDAQ in 2004, the company became an affiliate of Polaris Group in 2024, benefiting from group human resources and AI technology collaboration. It produces over 60 types of active pharmaceutical ingredients (APIs) using organic synthesis and chiral technologies, conducting both API and CDMO businesses. The company aims to expand its CDMO services to include development and production, adapting to AI technology shifts in the pharmaceutical and bio industries, including AI new drugs. Polaris AI Pharma was founded in 1998 and is headquartered in Hwaseong-si, Gyeonggi-do.